Today's Rundown Featured Story | | | Thursday, March 28, 2019 Health experts have rounded on pharma companies as having “endless talk and no action” when it comes to antibiotic R&D, as governments around the world continue to sound alarm bells over a potential antimicrobial resistance “apocalypse.” |
|
|
Top Stories Thursday, March 28, 2019 AstraZeneca has signed on to be a founding partner for a new life sciences research hub in China, to be housed just west of Shanghai. Thursday, March 28, 2019 Astellas and Seattle Genetics are preparing to file for FDA approval of enfortumab on the strength of phase 2 data. The trial linked the antibody-drug conjugate to a 44% response rate in patients with locally advanced or metastatic urothelial cancer. Thursday, March 28, 2019 Polyneuron Pharmaceuticals has raised CHF 22.5 million ($22.6 million) to run a phase 1 trial in a rare autoimmune disease. Sofinnova Partners and New Enterprise Associates co-led the investment in the startup on the strength of its technology for eliminating pathological autoantibodies. Thursday, March 28, 2019 Following on the heels of Pfizer and Janssen, AstraZeneca has signed up to use Ichor Medical Systems’ platform aimed at delivering plasmid DNA into cells through electrical pulses. Thursday, March 28, 2019 By targeting the body’s lymph nodes with anti-cancer vaccines, new immunotherapy developer Elicio Therapeutics aims to focus on ground zero of the body’s immune system. And to do it, the startup is getting underway with $30 million in funds, a new CEO and tech from the Massachusetts Institute of Technology. | This week's sponsor is Covance. | |  | Advancing a Diabetes Multi-Registration Program
Learn how Covance helped a sponsor who wanted to get all sites for a 2,700 patient study up and running as quickly as possible. Covance leveraged their proprietary historical investigator performance database to see which investigators outperformed their peers on a consistent basis and had the capacity to run multiple studies at the same time. Download the Case Study now. |
Resources Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Patheon, part of Thermo Fisher Scientific The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: ON24 Which HCP Touchpoints and channels are yielding the best results in today’s digital world? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
